Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease (Q34540703)

2 August 2017

1 reference

title

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

2 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Arun J Sanyal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

19 September 2016

1 reference

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

180-190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

PPARs: fatty acid sensors controlling metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Practice patterns in NAFLD and NASH: real life differs from published guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Treatment of NASH with ursodeoxycholic acid: pro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Bile acid binding to sevelamer HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Malonyl-CoA: the regulator of fatty acid synthesis and oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

A lipidomic analysis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Statin use and non-alcoholic steatohepatitis in at risk individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

MicroRNAs 103 and 107 regulate insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Vitamin E and transfer proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Vitamin E and all-cause mortality: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Apoptosis and cytokines in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Apoptosis in alcoholic and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

First-in-class pan caspase inhibitor developed for the treatment of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Prednisolone or pentoxifylline for alcoholic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The protein kinase IKKepsilon regulates energy balance in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The role of chemokines in acute liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Roles for chemokines in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Therapy of experimental NASH and fibrosis with galectin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312431

10.1136/GUTJNL-2016-312431

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27646933%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference